

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number
WO 2004/000831 A1

(51) International Patent Classification⁷: **C07D 401/14**,
405/14, 409/14, 471/04, A61K 31/445, A61P 25/06,
25/18, 25/28, 25/20, 27/14

ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV,
MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH,
PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UZ, VC, VN, YU, ZA, ZM.

(21) International Application Number:

PCT/US2003/019619

(22) International Filing Date: 20 June 2003 (20.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/390,987

24 June 2002 (24.06.2002) US

(71) Applicant: SCHERING CORPORATION [US/US];
2000 Galloping Hill Road, Kenilworth, NJ 07033-0530
(US).

(72) Inventors: ASLANIAN, Robert, G.; 144 Philip Drive,
Rockaway, NJ 07866 (US). BERLIN, Michael, Y.; 14
Hendrick Road, Flemington, NJ 08822 (US). MANGIA-
RACINA, Pietro; 4 Montclair Avenue, Monsey, NY 10952
(US). MC CORMICK, Kevin, D.; 5 Pace Drive, Edison,
NJ 08820 (US). MUTAHI, Mwangi, W.; 532 Berkeley Ave-
nue, Orange, NJ 07050 (US). ROSENBLUM, Stuart, B.;
16 Steven Terrace, West Orange, NJ 07052 (US).

(74) Agent: MAGATTI, Anita, W.; Schering-Plough Corpora-
tion, Patent Department -K-6-1 1990, 2000 Galloping Hill
Road, Kenilworth, NJ 07033-0530 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ,
DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations


Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/000831 A1

(54) Title: INDOLE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS



(57) Abstract: Disclosed are novel compounds of the formula I wherein M¹ is CH or N and M² is C(R³) or N; R¹ is optionally substituted indolyl or an aza derivative thereof; R² is optionally substituted aryl or heteroaryl; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g.,

nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I in combination with a H₁ receptor antagonist.

BEST AVAILABLE COPY

INDOLE DERIVATIVES USEFUL AS HISTAMINE H₃ ANTAGONISTS

10

FIELD OF THE INVENTION

The present invention relates to novel substituted indoles and derivatives thereof, useful as histamine H₃ antagonists. The invention also relates to pharmaceutical compositions comprising said compounds and their use in treating
15 inflammatory diseases, allergic conditions and central nervous system disorders. The invention also relates to the use of a combination of novel histamine H₃ antagonists of this invention with histamine H₁ compounds for the treatment of inflammatory diseases and allergic conditions, as well as pharmaceutical compositions comprising a combination of one or more novel histamine H₃ antagonist compounds of the
20 invention with one or more histamine H₁ compounds.

BACKGROUND OF THE INVENTION

The histamine receptors, H₁, H₂ and H₃ are well-identified forms. The H₁ receptors are those that mediate the response antagonized by conventional
25 antihistamines. H₁ receptors are present, for example, in the ileum, the skin, and the bronchial smooth muscle of humans and other mammals. Through H₂ receptor-mediated responses, histamine stimulates gastric acid secretion in mammals and the chronotropic effect in isolated mammalian atria.


H₃ receptor sites are found on sympathetic nerves, where they modulate
30 sympathetic neurotransmission and attenuate a variety of end organ responses under control of the sympathetic nervous system. Specifically, H₃ receptor activation by histamine attenuates nonpinephrine outflow to resistance and capacitance vessels, causing vasodilation.

Imidazole H₃ receptor antagonists are well known in the art. More recently, non-imidazole H₃ receptor antagonists have been disclosed in PCT US01/32151, filed October 15, 2001, and US Application 10/095,134, filed March 11, 2002.

US 5,869,479 discloses compositions for the treatment of the symptoms of allergic rhinitis using a combination of at least one histamine H₁ receptor antagonist and at least one histamine H₃ receptor antagonist.

SUMMARY OF THE INVENTION

The present invention provides novel compounds of formula I:



or a pharmaceutically acceptable salt or solvate thereof, wherein:

a is 0 to 3;

b is 0 to 3;

n is 1, 2 or 3;

p is 1, 2 or 3;

r is 0, 1, 2, or 3;

X is a bond or C₁-C₆ alkylene;

M¹ is CH or N;


M² is C(R³) or N;

with the provisos that when M² is N, p is not 1; and that when r is 0, M² is C(R³); and that the sum of p and r is 1 to 4;

Y is -C(=O)-, -C(=S)-, -(CH₂)_q-, -NR⁴C(=O)-, -C(=O)NR⁴-, -C(=O)CH₂-, -SO₁₋₂-, -C(=N-CN)-NH- or -NH-C(=N-CN)-; with the provisos that when M¹ is N, Y is not -NR⁴C(=O)- or -NH-C(=N-CN)-; and when M² is N, Y is not -C(=O)NR⁴- or -C(=N-CN)-NH-;

q is 1 to 5, provided that when M¹ and M² are both N, q is not 1;

Z is a bond, C₁-C₆ alkylene, C₂-C₆ alkenylene, -C(=O)-, -CH(CN)- or -CH₂C(=O)NR⁴-;



Q is $-N(R^8)-$, $-S-$ or $-O-$;

k is 0, 1, 2, 3 or 4;

5 k1 is 0, 1, 2 or 3;

k2 is 0, 1 or 2;


the dotted line represents an optional double bond;

R and R^7 are independently selected from the group consisting of H, C_1-C_6 alkyl, halo(C_1-C_6)alkyl-, C_1-C_6 alkoxy, (C_1-C_6)alkoxy-(C_1-C_6)alkyl-, (C_1-C_6)-alkoxy-
 10 (C_1-C_6)alkoxy, (C_1-C_6)alkoxy-(C_1-C_6)alkyl- $SO_{0.2}$, R^{32} -aryl(C_1-C_6)alkoxy-, R^{32} -aryl-
 (C_1-C_6)alkyl-, R^{32} -aryl, R^{32} -aryloxy, R^{32} -heteroaryl, (C_3-C_6)cycloalkyl, (C_3-C_6)cycloalkyl-
 (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl-(C_1-C_6)alkoxy, (C_3-C_6)cycloalkyl-oxy-, R^{37} -heterocyclo-
 alkyl, $N(R^{30})(R^{31})-(C_1-C_6)$ alkyl-, $-N(R^{30})(R^{31})$, $-NH-(C_1-C_6)$ alkyl-O-(C_1-C_6)alkyl,
 $-NHC(O)NH(R^{29})$; $R^{22}-S(O)_{0.2-}$, halo(C_1-C_6)alkyl-S(O) $_{0.2-}$, $N(R^{30})(R^{31})-(C_1-C_6)$ alkyl-
 15 $S(O)_{0.2-}$, benzoyl, (C_1-C_6)alkoxy-carbonyl, R^{37} -heterocycloalkyl- $N(R^{29})-C(O)-$, (C_1-
 C_6)alkyl- $N(R^{29})-C(O)-$, (C_1-C_6)alkyl- $N(C_1-C_6$ alkoxy)- $C(O)-$, $-C(=NOR^{36})R^{36}$ and
 $-NHC(O)R^{29}$; and when the optional double bond is not present, R^7 can be OH;

R^8 is H, C_1-C_6 alkyl, halo(C_1-C_6)alkyl-, (C_1-C_6)alkoxy-(C_2-C_6)alkyl-, R^{32} -aryl(C_1-
 C_6)alkyl-, R^{32} -aryl, R^{32} -heteroaryl, R^{32} -heteroaryl(C_1-C_6)alkyl-, (C_3-C_6)cycloalkyl, (C_3-
 20 C_6)cycloalkyl-(C_1-C_6)alkyl, R^{37} -heterocycloalkyl, R^{37} -heterocycloalkyl(C_1-C_6)alkyl,
 $N(R^{30})(R^{31})-(C_2-C_6)$ alkyl-, $R^{22}-S(O)_{2-}$, halo(C_1-C_6)alkyl-S(O) $_{2-}$, $R^{22}-S(O)_{0.1-}(C_2-C_6)$ alkyl-,
 halo(C_1-C_6)alkyl-S(O) $_{0.1-}(C_2-C_6)$ alkyl-, (C_1-C_6)alkyl- $N(R^{29})-SO_{2-}$, or R^{32} -heteroaryl- SO_2 ;

R^2 is a six-membered heteroaryl ring having 1 or 2 heteroatoms independently selected from N or N-O, with the remaining ring atoms being carbon; a five-

membered heteroaryl ring having 1, 2, 3 or 4 heteroatoms independently selected from N, O or S, with the remaining ring atoms being carbon; R³²-quinolyl; R³²-aryl;



or heterocycloalkyl; wherein said six-membered heteroaryl ring or said five-membered heteroaryl ring is optionally substituted by R⁶;

R³ is H, halogen, C₁-C₆ alkyl, -OH or (C₁-C₆)alkoxy;

R⁴ is independently selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, (C₃-C₆)cycloalkyl(C₁-C₆)alkyl, R³³-aryl, R³³-aryl(C₁-C₆)alkyl, and R³²-heteroaryl;

R⁵ is hydrogen, C₁-C₆ alkyl, -C(O)R²⁰, -C(O)₂R²⁰, -C(O)N(R²⁰)₂, R³³-aryl(C₁-C₆)alkyl or (C₁-C₆)alkyl-SO₂;

R⁶ is 1 to 3 substituents independently selected from the group consisting of -OH, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, -CF₃, -NR⁴R⁵, -(C₁-C₆)alkyl-NR⁴R⁵, phenyl, R³³-phenyl, NO₂, -CO₂R⁴, -CON(R⁴)₂, -NHC(O)N(R⁴)₂, R³²-heteroaryl-SO₂-NH-, R³²-aryl-(C₁-C₆)alkyl-NH-, R³²-heteroaryl-(C₁-C₆)alkyl-NH-, R³²-heteroaryl-NH-C(O)-NH-, R³⁷-heterocycloalkyl-N(R²⁹)-C(O)- and R³⁷-heterocycloalkyl-N(R²⁹)-C(O)-NH-;

R¹² is independently selected from the group consisting of C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, or fluoro, provided that when R¹² is hydroxy or fluoro, then R¹² is not bound to a carbon adjacent to a nitrogen; or R¹² forms a C₁ to C₂ alkyl bridge from one ring carbon to another ring carbon;

R¹³ is independently selected from the group consisting of C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, or fluoro, provided that when R¹³ is hydroxy or fluoro then R¹³ is not bound to a carbon adjacent to a nitrogen; or forms a C₁ to C₂ alkyl bridge from one ring carbon to another ring carbon; or R¹³ is =O;

R²⁰ is independently selected from the group consisting of hydrogen, C₁-C₆ alkyl, or aryl, wherein said aryl group is optionally substituted with from 1 to 3 groups independently selected from halogen, -CF₃, -OCF₃, hydroxyl, or methoxy; or when two R²⁰ groups are present, said two R²⁰ groups taken together with the nitrogen to which they are bound can form a five or six membered heterocyclic ring;

R²² is C₁-C₆ alkyl, R³⁴-aryl or heterocycloalkyl;

R²⁴ is H, C₁-C₆ alkyl, -SO₂R²² or R³⁴-aryl;

R^{25} is independently selected from the group consisting of C_1 - C_6 alkyl, halogen, CN, $-CF_3$, $-OH$, C_1 - C_6 alkoxy, $(C_1-C_6)alkyl-C(O)-$, $aryl-C(O)-$, $N(R^4)(R^5)-C(O)-$, $N(R^4)(R^5)-S(O)_{1-2}-$, halo- $(C_1-C_6)alkyl-$ or halo- $(C_1-C_6)alkoxy-(C_1-C_6)alkyl-$;

R^{29} is H, C_1 - C_6 alkyl, R^{35} -aryl or R^{35} -aryl(C_1 - C_6)alkyl-;

5 R^{30} is H, C_1 - C_6 alkyl-, R^{35} -aryl or R^{35} -aryl(C_1 - C_6)alkyl-;

R^{31} is H, C_1 - C_6 alkyl-, R^{35} -aryl, R^{35} -aryl(C_1 - C_6)alkyl-, $(C_1-C_6)alkyl-C(O)-$, R^{35} -aryl- $C(O)-$, $N(R^4)(R^5)-C(O)-$, $(C_1-C_6)alkyl-S(O)_2-$ or R^{35} -aryl- $S(O)_2-$;

or R^{30} and R^{31} together are $-(CH_2)_{4-5}-$, $-(CH_2)_2-O-(CH_2)_2-$ or $-(CH_2)_2-N(R^{29})-(CH_2)_2-$ and form a ring with the nitrogen to which they are attached;

10 R^{32} is 1 to 3 substituents independently selected from the group consisting of H, $-OH$, halogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, R^{35} -aryl-O-, $-SR^{22}$, $-CF_3$, $-OCF_3$, $-OCHF_2$, $-NR^4R^5$, phenyl, R^{33} -phenyl, $-NO_2$, $-CO_2R^4$, $-CON(R^4)_2$, $-S(O)_2R^{22}$, $-S(O)_2N(R^{20})_2$, $-N(R^{24})S(O)_2R^{22}$, $-CN$, hydroxy- $(C_1-C_6)alkyl-$, $-OCH_2CH_2OR^{22}$, and R^{35} -aryl(C_1 - C_6)alkyl-O-, wherein said aryl group is optionally substituted with 1 to 3 independently
15 selected halogens;

R^{33} is 1 to 3 substituents independently selected from the group consisting of C_1 - C_6 alkyl, halogen, $-CN$, $-NO_2$, $-OCHF_2$ and $-O-(C_1-C_6)alkyl$;

R^{34} is 1 to 3 substituents independently selected from the group consisting of H, halogen, $-CF_3$, $-OCF_3$, $-OH$ and $-OCH_3$.

20 R^{35} is 1 to 3 substituents independently selected from the group consisting of hydrogen, halo, C_1 - C_6 alkyl, hydroxy, C_1 - C_6 alkoxy, phenoxy, $-CF_3$, $-N(R^{36})_2$, $-COOR^{20}$ and $-NO_2$;

R^{36} is independently selected from the group consisting of H and C_1 - C_6 alkyl;
and

25 R^{37} is independently selected from the group consisting of H, C_1 - C_6 alkyl and $(C_1-C_6)alkoxycarbonyl$.

This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula I and a pharmaceutically
30 acceptable carrier.

This invention further provides a method of treating: allergy, allergy-induced airway (e.g., upper airway) responses, congestion (e.g., nasal congestion), hypotension, cardiovascular disease, diseases of the GI tract, hyper- and hypomotility and acidic secretion of the gastro-intestinal tract, obesity, sleeping disorders

(e.g., hypersomnia, somnolence, and narcolepsy), disturbances of the central nervous system, attention deficit hyperactivity disorder (ADHD), hypo- and hyperactivity of the central nervous system (for example, agitation and depression), and/or other CNS disorders (such as Alzheimer's, schizophrenia, and migraine) comprising administering to a patient in need of such treatment an effective amount of at least one compound of formula I. "Patient" means a mammal, typically a human, although veterinary use is also contemplated.

Compounds of this invention are particularly useful for treating allergy, allergy-induced airway responses and/or congestion.

10 This invention further provides a pharmaceutical composition comprising an effective amount of a combination of at least one compound of formula I and at least one H₁ receptor antagonist in combination with a pharmaceutically acceptable carrier.

This invention further provides a method of treating allergy, allergy-induced airway (e.g., upper airway) responses, and/or congestion (e.g., nasal congestion) comprising administering to a patient in need of such treatment (e.g., a mammal, such as a human being) an effective amount of a combination of at least one compound of formula I and at least one H₁ receptor antagonist.

Kits comprising a compound of formula I in a pharmaceutical composition, and a separate H₁ receptor antagonist in a pharmaceutical composition in a single package are also contemplated.

DETAILED DESCRIPTION OF THE INVENTION

Preferred definitions of the variables in the structure of formula I are as follows:

25 R¹ is preferably 3-indolyl or 1-indolyl. The double bond is preferably present in the R¹ substituent.

R is preferably H, alkyl, R³²-aryl, R³²-heteroaryl, (C₁-C₆)alkoxy-carbonyl or (C₁-C₆)alkyl-N(R²⁹)-C(O)-. When R is (C₁-C₆)alkyl-N(R²⁹)-C(O)-, R²⁹ is preferably H or C₁-C₆ alkyl. More preferably, R is R³²-aryl or R³²-heteroaryl. Especially preferred are R³²-phenyl and R³²-pyridyl. R⁷ is preferably H.

30 R⁸ is preferably H, R³²-aryl(C₁-C₆)alkyl-, R³²-heteroaryl(C₁-C₆)alkyl-, R³²-aryl, R³²-heteroaryl, (C₁-C₆)alkyl-N(R²⁹)-SO₂- or R³⁷-heterocycloalkyl(C₁-C₆)alkyl-. Especially preferred are H, R³²-benzyl, R³²-pyridylmethyl, (C₁-C₆)alkyl-N(R²⁹)-SO₂- wherein R²⁹ is H or C₁-C₆ alkyl, and piperidinoethyl.

R^{25} is preferably H, halogen or $-CF_3$ and k is 0 or 1. When R^1 is an aza- or diaza derivative of indole, R is preferably as defined above, and k_1 and k_2 are preferably zero.

X is preferably a bond.

5 R^2 is preferably a six-membered heteroaryl ring, optionally substituted with one substituent. More preferably, R^2 is pyridyl, pyrimidyl or pyridazinyl, optionally substituted with $-NH_2$.

Y is preferably $-C(O)-$.

10 Z is preferably straight or branched C_1 - C_3 alkyl. Methylene is an especially preferred Z group.

M^1 is preferably N; a is preferably 0; and n is preferably 2; the optional double bond in the ring containing M^1 is preferably not present (i.e., a single bond is present).

15 M^2 is preferably $C(R^3)$ wherein R^3 is hydrogen or fluoro; b is preferably 0; r is preferably 1; and p is preferably 2.

As used herein, the following terms have the following meanings, unless indicated otherwise:

20 alkyl (including, for example, the alkyl portions of arylalkyl and alkoxy) represents straight and branched carbon chains and contains from one to six carbon atoms;

alkylene represents a divalent straight or branched alkyl chain, e.g., ethylene ($-CH_2-$) or propylene ($-CH_2CH_2CH_2-$);

25 haloalkyl or haloalkoxy represent alkyl or alkoxy chains as defined above wherein one or more hydrogen atoms are replaced by halogen atoms, e.g., $-CF_3$, $CF_3CH_2CH_2-$, CF_3CF_2- or CF_3O- ;

aryl (including the aryl portion of arylalkyl) represents a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g., aryl is a phenyl or naphthyl ring), with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment;

30 arylalkyl represents an aryl group, as defined above, bound to an alkyl group, as defined above, wherein said alkyl group is bound to the compound;


cycloalkyl represents saturated carbocyclic rings of from 3 to 6 carbon atoms;

halogen (halo) represents fluoro, chloro, bromo and iodo;


heteroaryl represents cyclic groups, having 1 to 4 heteroatoms selected from O, S or N, said heteroatom interrupting a carbocyclic ring structure and having a sufficient number of delocalized pi electrons to provide aromatic character, with the aromatic heterocyclic groups preferably containing from 2 to 14 carbon atoms. The rings do not contain adjacent oxygen and/or sulfur atoms. Examples include but are not limited to isothiazolyl, isoxazolyl, oxazolyl, furazanyl, triazolyl, tetrazolyl, thiazolyl, thienyl, furanyl (furyl), pyrrolyl, pyrazolyl, pyranyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyridyl (e.g., 2-, 3-, or 4-pyridyl), pyridyl N-oxide (e.g., 2-, 3-, or 4-pyridyl N-oxide), triazinyl, pteridinyl, indolyl (benzopyrrolyl), pyridopyrazinyl, isoquinolinyl, quinolinyl, naphthyridinyl; the 5- and 6-membered heteroaryl groups included in the definition of R^2 are exemplified by the heteroaryl groups listed above; all available substitutable carbon and nitrogen atoms can be substituted as defined.

heterocycloalkyl represents a saturated, carbocyclic ring containing from 3 to 15 carbon atoms, preferably from 4 to 6 carbon atoms, which carbocyclic ring is interrupted by 1 to 3 hetero atoms selected from -O-, -S-, -SO-, -SO₂ or -NR⁴⁰- wherein R⁴⁰ represents H, C₁ to C₆ alkyl, arylalkyl, -C(O)R²⁰, -C(O)OR²⁰, or -C(O)N(R²⁰)₂ (wherein each R²⁰ is independently selected); examples include but are not limited to 2- or 3-tetrahydrofuranyl, 2- or 3-tetrahydrothienyl, 2-, 3- or 4-piperidinyl, 2- or 3-pyrrolidinyl, 2- or 3-piperizinyl, 2- or 4-dioxanyl, 1,3-dioxolanyl, 1,3,5-trithianyl, pentamethylene sulfide, perhydroisoquinolinyl, decahydroquinolinyl, trimethylene oxide, azetidiny, 1-azacycloheptanyl, 1,3-dithianyl, 1,3,5-trioxanyl, morpholinyl, thiomorpholinyl, 1,4-thioxanyl, and 1,3,5-hexahydrotriazinyl, thiazolidinyl, tetrahydropyranyl.

(N) , for example in the structure



represents a nitrogen atom that is located at one of the 4 non-fused positions of the ring, i.e., positions 4, 5, 6 or 7 indicated below:



Similarly, $\textcircled{2N}$ means that two nitrogen atoms are located at any two of the 4 non-fused positions of the ring, e.g., the 4 and 6 positions, the 4 and 7 positions, or the 5 and 6 positions.

- 5 A dotted line in the structure of formula I or in the structures defining R^1 indicates an option double bond. The presence or absence of a double bond in the structure of formula I is independent of the presence or absence of a double bond in the R^1 substituent.

Also, as used herein, "upper airway" usually means the upper respiratory system--i.e., the nose, throat, and associated structures.

Also, as used herein, "effective amount" generally means a therapeutically effective amount.

A line drawn into a ring means that the indicated bond may be attached to any of the substitutable ring carbon atoms.

- 15 Certain compounds of the invention may exist in different isomeric (e.g., enantiomers, diastereoisomers and geometric) forms. The invention contemplates all such isomers both in pure form and in admixture, including racemic mixtures. Enol forms and tautomers are also included.

The compounds of this invention are ligands for the histamine H_3 receptor.

20 The compounds of this invention can also be described as antagonists of the H_3 receptor, or as H_3 antagonists.

The compounds of the invention are basic and form pharmaceutically acceptable salts with organic and inorganic acids. Examples of suitable acids for such salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those skilled in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner. The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as

25

dilute aqueous sodium hydroxide, potassium carbonate, ammonia and sodium bicarbonate. The free base forms can differ from their corresponding salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the salts are otherwise equivalent to their corresponding free base forms for purposes of
5 this invention.

Depending upon the substituents on the inventive compounds, one may be able to form salts with bases. Thus, for example, if there is a carboxylic acid substituent in the molecule, a salt may be formed with an inorganic as well as organic base such as, for example, NaOH, KOH, NH₄OH, tetraalkylammonium hydroxide, and
10 the like.

The compounds of formula I can exist in unsolvated as well as solvated forms, including hydrated forms, e.g., hemi-hydrate. In general, the solvated form, with pharmaceutically acceptable solvents such as water, ethanol and the like are equivalent to the unsolvated form for purposes of the invention.

15 The compounds of this invention can be combined with an H₁ receptor antagonist (i.e., the compounds of this invention can be combined with an H₁ receptor antagonist in a pharmaceutical composition, or the compounds of this invention can be administered with an H₁ receptor antagonist).

Numerous chemical substances are known to have histamine H₁ receptor
20 antagonist activity and can therefore be used in the methods of this invention. Many H₁ receptor antagonists useful in the methods of this invention can be classified as ethanolamines, ethylenediamines, alkylamines, phenothiazines or piperidines. Representative H₁ receptor antagonists include, without limitation: astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, chlorpheniramine,
25 clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, diphenhydramine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, meclizine, mizolastine, mequitazine, mianserin, noberastine, norastemizole, picumast, pyrilamine, promethazine, terfenadine, tripeleminamine,
30 temelastine, trimeprazine and triprolidine. Other compounds can readily be evaluated to determine activity at H₁ receptors by known methods, including specific blockade of the contractile response to histamine of isolated guinea pig ileum. See for example, WO98/06394 published February 19, 1998.

Those skilled in the art will appreciate that the H₁ receptor antagonist is used at its known therapeutically effective dose, or the H₁ receptor antagonist is used at its normally prescribed dosage.

Preferably, said H₁ receptor antagonist is selected from: astemizole, azatadine, 5 azelastine, acrivastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, diphenhydramine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, meclizine, mizolastine, mequitazine, mianserin, noberastine, norastemizole, picumast, 10 pyrilamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine or triprolidine.

More preferably, said H₁ receptor antagonist is selected from: astemizole, azatadine, azelastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, carebastine, descarboethoxyloratadine, diphenhydramine, doxylamine, ebastine, 15 fexofenadine, loratadine, levocabastine, mizolastine, norastemizole, or terfenadine.

Most preferably, said H₁ receptor antagonist is selected from: azatadine, brompheniramine, cetirizine, chlorpheniramine, carebastine, descarboethoxy- loratadine, diphenhydramine, ebastine, fexofenadine, loratadine, or norastemizole.

Even more preferably, said H₁ antagonist is selected from loratadine, 20 descarboethoxyloratadine, fexofenadine or cetirizine. Still even more preferably, said H₁ antagonist is loratadine or descarboethoxyloratadine.

In one preferred embodiment, said H₁ receptor antagonist is loratadine.

In another preferred embodiment, said H₁ receptor antagonist is 25 descarboethoxyloratadine.

In still another preferred embodiment, said H₁ receptor antagonist is 30 fexofenadine.

In yet another preferred embodiment, said H₁ receptor antagonist is cetirizine.

Preferably, in the above methods, allergy-induced airway responses are 35 treated.

Also, preferably, in the above methods, allergy is treated.


Also, preferably, in the above methods, nasal congestion is treated.

In the methods of this invention wherein a combination of an H₃ antagonist of this invention (compound of formula I) is administered with an H₁ antagonist, the antagonists can be administered simultaneously or sequentially (first one and then


the other over a period of time). In general, when the antagonists are administered sequentially, the H₃ antagonist of this invention (compound of formula I) is administered first.

The preparation of compounds of Formula I can be realized in many ways known to those skilled in the art. Following are typical procedures for preparing various compounds; other procedures may also be applicable and the procedures may be modified to prepare other compounds within the scope of Formula I. One skilled in the art will recognize that one route will be optimal depending on the choice of appendage substituents. Additionally, one skilled in the art will recognize that in some cases the order of steps has to be controlled to avoid functional group incompatibilities.

The structure of formula I can be considered to be made up of four parts, A, B, C and D, as shown below:




One possible route for preparing compounds of formula I involves a linear sequence of reactions to obtain the desired compounds, i.e.,



The synthesis using this approach is given below for compounds in which R¹ is 3-indolyl, M¹ is N, M² is CH, and Y is -C(O)-:


A + B → AB



Indole (1), obtained commercially or through procedures well known in the art, is reacted under acidic conditions such as acetic acid and phosphoric acid or the like at a temperature of 20°-100° C with a ketone for a time sufficient to complete the reaction to give compound (2). Compound (2) can be reduced using a metal catalyst such as palladium, platinum or the like in a solvent such as methanol, ethanol, ethyl

acetate or the like at a temperature from 20°-50° C under an atmosphere of hydrogen or in the presence of a hydrogen source such as NH_4Cl or NH_4HCO_2 to give the fragment **AB**. Other **AB** ring analogs can be prepared using procedures well known to those versed in the art, see for example *J. Heterocyclic Chem.*, 30, (1993), 445, US 5,846,982, WO 01/46181, and EP 470039.


AB + C → ABC



Amine **AB** can be coupled to acid **C**, wherein PG is a protecting group, using a number of methods well known in the art such as using EDC, DCC or PyBOP (benzotriazole-1-yl-oxy-trispyrrolidino-phosphonium hexafluorophosphate). Alternatively, the acid **C** can be activated by conversion to the acid chloride or mixed anhydride and then reacted with the amine **AB** to give **ABC**. Suitable protecting groups for **C** include t-BOC or the like.


ABC + D → ABCD

Step 1



Compound **ABC** is deprotected using conditions suitable for the removal of the protecting group, PG, to give **ABC''**.

Step 2




For compounds wherein $\text{Z-R}^2 = -(\text{CH}_2)_{1-6}\text{-R}^2$, **ABC''** can be reacted with an aldehyde of the formula $\text{R}^2(\text{CH}_2)_{1-5}\text{CHO}$ in the presence of a reducing agent such as NaBH_4 , $\text{NaBH}(\text{OAc})_3$ or the like, in a suitable solvent such as methanol, ethanol,

dichloromethane or the like, to give **ABCD**. Alternatively, **ABC** can be reacted with an alkylating agent $R^2-(CH_2)-X$, in which X is a leaving group such as a halogen or mesylate or the like, in a solvent such as DMSO, DMF or the like, in the presence of a base, to give **ABCD**.

- 5 For compounds wherein $Z-R^2 = C(O)-R^2$, **ABC** can be coupled with an acid R^2CO_2H in the presence of a coupling agent such as EDC, DCC or PyBOP. Alternatively, the acid can be activated by conversion to the acid chloride or mixed anhydride and then reacted with the amine **ABC** to give **ABCD**.


- 10 Other reagents can also be utilized in a similar fashion to introduce $Z-R^2$, including for example, sulfonyl halides, R^2SO_2X , or isocyanates of the formula R^2NCO .

Introduction of R^8 :




- For compounds wherein R^8 is attached to the indole nitrogen via an alkyl chain, R^8 can be introduced by reacting the indole nitrogen with an alkylating agent R^8-X , in which X is a leaving group such as a halogen or mesylate or the like, in a solvent like DMSO, DMF or the like, in the presence of a base to give the final product. For compounds wherein R^8 is attached to the indole nitrogen through a -
 15 SO_2 - group, the indole nitrogen is reacted with a sulfonyl chloride in the presence of a
 20 base such as Et_3N in a solvent such as CH_2Cl_2 at a temperature of $0^\circ-80^\circ C$.

An alternate approach to the synthesis of compounds of formula I comprises the synthesis of the two halves of the molecule (**AB** and **CD**), followed by coupling of the two pieces i.e.:



The synthesis of the **AB** fragment is the same as previously described. The **CD** fragment is synthesized as shown below.

C + D → CD


Step 1

For $\text{Z-R}^2 = -(\text{CH}_2)_{1-6}\text{-R}^2$, **C** can be reacted with an aldehyde of the formula $\text{R}^2(\text{CH}_2)_{1-5}\text{CHO}$ in the presence of a reducing agent such as NaBH_4 , $\text{NaBH}(\text{OAc})_3$ or the like in a suitable solvent such as methanol, ethanol, dichloromethane or the like to give **CD**. Alternatively, **C** can be reacted with an alkylating agent $\text{R}^2-(\text{CH}_2)_{1-6}\text{-X}$, in which X is a leaving group such as a halogen, mesylate or the like, in a solvent such as DMSO, DMF or the like, in the presence of a base to give **CD**.


For $\text{Z-R}^2 = \text{C}(\text{O})\text{-R}^2$, **C** can be coupled with an acid $\text{R}^2\text{CO}_2\text{H}$ in the presence of a coupling agent such as EDC, DCC or PyBOP. Alternatively, the acid can be activated by conversion to the acid chloride or mixed anhydride and then reacted with the amine **C** to give **CD**.

Other reagents can also be utilized in a similar fashion to introduce Z-R^2 , including for example, sulfonyl halides, $\text{R}^2\text{SO}_2\text{X}$, or isocyanates of the formula R^2NCO .

Step 2



Compound **CD** is saponified in a mixed solvent such as a combination of EtOH or CH_3OH and water, or a combination of THF, water, and CH_3OH , using an alkali metal base such as LiOH or NaOH at a temperature of from 20 to 100 °C to give **CD'**.

AB + CD' → ABCD

Amine **AB** can be coupled to **CD'** using a number of methods well known in the art, such as by using EDC, DCC or PyBOP. Alternatively, **CD'** can be activated

by conversion to the acid chloride or mixed anhydride and then reacted with the amine **AB** to give **ABCD**.

The starting material and reagents used in preparing compounds described are either available from commercial suppliers such as Aldrich Chemical Co.

5 (Wisconsin, USA) and Acros Organics Co. (New Jersey, USA) or were prepared by literature methods known to those skilled in the art.

Compounds of formula I can be prepared by the general methods outlined above. Specifically exemplified compounds were prepared as described in the examples below, from starting materials known in the art or prepared as described
10 below. These examples are being provided to further illustrate the present invention. They are for illustrative purposes only; the scope of the invention is not to be considered limited in any way thereby.

Unless otherwise stated, the following abbreviations have the stated meanings in the Examples below:

15 Me=methyl; Et=ethyl; Bu=butyl; Pr=propyl; Ph=phenyl; t-BOC=tert-butoxycarbonyl; and Ac=acetyl

DCC= dicyclohexylcarbodiimide

DMAP=4-dimethylaminopyridine

DMF=dimethylformamide

20 EDCI= 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide

HOBT= 1-hydroxybenzotriazole

NaBH(OAc)₃= sodium triacetoxymethylborohydride

RT=room temperature

TFA=trifluoroacetic acid

25 THF=tetrahydrofuran

TEMPO=2,2,6,6-tetramethyl-1-piperidinyloxy, free radical

TLC=thin layer chromatography

HRMS= High Resolution Mass Spectrometry



LRMS= Low Resolution Mass Spectrometry

30 nM= nanomolar

K_i= Dissociation Constant for substrate/receptor complex


pA₂= -logEC₅₀, as defined by J. Hey, *Eur. J. Pharmacol.*, (1995), Vol. 294, 329-335.

Ci/mmol= Curie/mmol (a measure of specific activity)


Preparation 1Step 1:

- 5 To a solution of 2-amino-4-methylpyridine (10.81 g, 100 mmol) in tert-butanol (250 ml) was added BOC anhydride (26.19 g, 120 mmol). The reaction mixture was stirred at RT overnight, concentrated – dry loaded on silica gel and flash chromatographed (from 30% hexanes/CH₂Cl₂ to 0-2% acetone/CH₂Cl₂) to produce 1 (15.25 g, 73.32 mmol; 73%) as a white solid.

10 Step 2:




- To a –78 °C solution of 1 (35.96 g, 173 mmol) in THF (1.4 l) was added n-BuLi (272 ml of a 1.4 M solution in hexanes, 381 mmol) in portions over 30 min. The reaction mixture was then allowed to warm up and was stirred for 2 h at RT, resulting in the formation of an orange precipitate. The mixture was cooled back to –78 °C, and pre-dried oxygen (passed through a Drierite column) was bubbled through the suspension for 6 h while the temperature was maintained at –78 °C. Reaction mixture color changed to yellow during this time. The reaction was then quenched at –78 °C with (CH₃)₂S (51.4 ml, 700 mmol), followed by AcOH (22 ml, 384 mmol). The reaction mixture was allowed to warm up and was stirred for 48 h at RT. Dilution with water and extraction with EtOAc were followed by concentration and flash chromatography (0–15% acetone/CH₂Cl₂) to provide alcohol 2 (20.15 g, 90 mmol; 52%) as a pale yellow solid.

Step 3:

To a solution of alcohol **2** (19.15 g, 85.5 mmol) in CH_2Cl_2 (640 ml) was added a saturated aqueous solution of NaHCO_3 (8.62 g, 103 mmol) and NaBr (444 mg, 4.3 mmol). The reaction mixture was cooled to 0°C , and TEMPO (140 mg, 0.90 mmol) was introduced. Upon vigorous stirring, commercial bleach solution (122 ml of 0.7 M, 85.4 mmol; 5.25% in NaOCl) was added in portions over 40 min. After an additional 20 min at 0°C , the reaction mixture was quenched with saturated aqueous $\text{Na}_2\text{S}_2\text{O}_3$ and allowed to warm to RT. Dilution with water and extraction with CH_2Cl_2 were followed by concentration and flash chromatography (from 30% hexanes/ CH_2Cl_2 to 0-2% acetone/ CH_2Cl_2) to afford aldehyde **3** (15.97 g, 71.9 mmol; 84%) as an off-white solid.

Step 4:





To a solution of aldehyde **3** (11.87 g, 53.5 mmol) in CH_2Cl_2 (370 ml) was added ethyl isonipecotate (9.07 ml, 58.8 mmol) followed by 4 drops of AcOH . The reaction mixture was then stirred for 40 min at RT, after which $\text{NaBH}(\text{OAc})_3$ (22.68 g, 107 mmol) was introduced. The reaction mixture was stirred overnight at RT, neutralized with saturated aqueous NaHCO_3 , diluted with water and extracted with CH_2Cl_2 . Concentration and flash chromatography (0-4% sat. NH_3 in $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$) provided **4** (19.09 mg, 52.6 mmol; 98%) as an off-white solid.

Step 5:


To a solution of ester **4** (1.57 g, 4.33 mmol) in a 3:1:1 mixture of THF:water: CH_3OH (10 ml) was added LiOH (0.125 g, 5.21 mmol). The reaction mixture was stirred overnight at RT, concentrated and exposed to high vacuum to obtain crude acid Preparation 1 (1.59 g) as a yellowish solid which was used without purification.

Preparation 2



Step 1:



To a solution of 5 (10 g, 79.4 mmol) and DMAP (0.029 g, 0.24 mmol) in CH_2Cl_2 (150 ml) at 0 °C was added phthaloyl dichloride (16.1 g, 79.4 mmol) dropwise. The reaction mixture was stirred at RT overnight, then washed with saturated aqueous NaHCO_3 , water, dried and concentrated to give compound 6 as a yellow solid (20 g, 99.8%) which was used without further purification.

Step 2:

A solution of compound 6, NBS and benzoyl peroxide in CCl_4 was refluxed at 80 °C for 5 h, cooled and stirred at RT overnight. The reaction was filtered and concentrated, and the residue was purified by flash column (30% EtOAc/Hexane) to obtain the desired compound 7.


Step 3:

Compound 7 (0.5 g, 1.5 mmol) and hydrazine (0.5 M in ethanol, 5 ml, 2.5 mmol) were combined and stirred at RT overnight. The reaction was diluted with water and extracted with CH_2Cl_2 . The organic layer was dried, concentrated and the residue purified on a flash column (3% CH_3OH in EtOAc) to give the title compound (0.2 g, 66%).

Preparation 3, 3A and 3BStep 1:


To a mixture of dialdehyde **19** (900 mg, 7.1 mmol) and guanidine hydrochloride (678 mg, 7.1 mmol) in absolute EtOH (20 ml) was added sodium ethoxide (483 mg, 7.1 mmol). The reaction mixture was heated at 90 °C for 12 h, cooled to RT, concentrated-dry loaded on silica gel and flash chromatographed (0-10% CH₃OH/ 20-30% acetone/ CH₂Cl₂) to produce **20** (355 mg, 2.9 mmol; 41%) as a yellowish solid. Alternatively, **20** can be prepared according to the procedure described in JP Patent 63227573.

Step 2:



To a mixture of **20** (166 mg, 1.35 mmol), DMAP (17 mg, 0.14 mmol) and Et₃N (418 µl, 3.00 mmol) in THF (10 ml) was added (BOC)₂O (589 mg, 2.7 mmol). The mixture was stirred at RT for 5 h, concentrated-dry loaded on silica gel and flash chromatographed (1-3% acetone/ CH₂Cl₂) to produce **21** (117 mg, 0.36 mmol; 27%) as a clear oil.

Step 3:




To a solution of aldehyde **21** (117 mg, 0.36 mmol) in CH₂Cl₂ (7 ml) was added ethyl isonipecotate (67 µl, 0.43 mmol) and AcOH (5 µl). 30 min. later, NaBH(OAc)₃ (153 mg, 0.72 mmol) was introduced. The mixture was stirred overnight at RT, diluted with CH₂Cl₂, washed with aqueous NaHCO₃, dried and concentrated, and the crude residue was flash chromatographed (0-4% sat. NH₃ in CH₃OH/CH₂Cl₂) to produce **22** (133 mg, 0.29 mmol; 81%) as a white film.

Step 4:

To a solution of **22** in a 3:1:1 mixture of THF:water: CH₃OH (5 ml) was added LiOH (11 mg, 0.44 mmol). The reaction mixture was stirred overnight at RT, concentrated to dryness and exposed to high vacuum to obtain Preparation 3 (134 mg) as a yellowish solid which was used without purification.


Using a similar procedure, but omitting Step 2, Preparation 3A is obtained.

Prep. 3B is prepared by substituting ethyl 4-(4-fluoropiperidine)carboxylate for ethyl isonipecotate. Ethyl 4-(4-fluoropiperidine)carboxylate is prepared according to the following procedure:



- 5 A solution of (a) (100g, 0.389 mol) in THF (400 ml) was added dropwise over 1.0 h to a solution of LDA (233 ml, 2.0 M in THF/heptane/ethyl-benzene, 0.466 mol) in THF (300ml) at 0 °C. The solution was stirred at 0 °C for 30 min, and then transferred by cannula to a 0 °C solution of N-fluorobenzenesulfonimide (153 g, 0.485 mol) in dry THF (600 ml). The reaction mixture was stirred at 0 °C for 30 min, and
 10 then at 20 °C for 18 h. The total solvent volume was reduced to approximately one third, and EtOAc (1l) was added. The solution was washed successively with water, 0.1 N aq. HCl, saturated aq. NaHCO₃, and brine. The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure to yield a crude liquid. Separation by flash chromatography (6:1 hexanes-EtOAc) gave compound (b) (93.5
 15 g, 87%). The BOC protecting group was removed using standard procedures known in the art.

Preparation 4, 4A, 4B, 4C, 4D, 4E






- 20 A solution of indole **31** (10 g) and piperidone hydrochloride (19.7 g) in glacial AcOH (100 ml) and H₃PO₄ (40 ml of 1 M solution in water) was heated to 80 °C and stirred for 90 min. The reaction mixture was then poured into ice-cooled NH₄OH (500 ml) and extracted thrice with EtOAc (200 ml) and twice with CH₂Cl₂ (200 ml). The
 25 organic extracts were combined and concentrated on the rotary evaporator to provide crude Preparation 4. Flash chromatography on silica gel, using 10-20% NH₃ saturated CH₃OH in CH₂Cl₂ as the eluant, provided pure Preparation 4.

Preparation 4A:


A solution of Preparation 4 (1.1 g) in CH₃OH (100 ml) was treated with 10 % Pd/C (250 mg) and ammonium formate (2.8 g) and refluxed overnight. The reaction mixture was filtered through celite. Concentration of the filtrate provided crude

5 Preparation 4A.

In a similar manner, Preparations 4B, 4C, 4D and 4E were prepared:

Preparation 510 Step 1:


3,4 Pyridine-dicarboximide (10.0 g, 67.5 mmol) was dissolved in 10% aqueous NaOH (162 g) and the solution was cooled to an internal temperature of 7 °C in an ice-salt bath. Bromine (3.6 ml; 70 mmol) was added dropwise. After the addition, the solution was heated for 45 min at a bath temperature of 80-85 °C. The yellow solution was then cooled to an internal temperature of 37 °C, and glacial AcOH (17 ml) were added dropwise to a pH of 5.5. The resulting mixture was refrigerated overnight. The solid formed was filtered and washed with water (5 ml) and CH₃OH (5 ml). The reaction yielded 6.35 g. of product, m.p. 280-285 °C (decomp.).

20 Step 2:

Solid compound 61 (9.5 g, 69 mmol) was carefully added in 3 aliquots to a slurry of LiAlH₄ (9.5 g, 250 mmol) in dry THF (200 ml). The resulting hot mixture was stirred at RT for 2 days. After cooling in an ice bath, the reaction was quenched with


careful sequential dropwise addition of water (10 ml), followed by 15% aqueous NaOH (10 ml), then by water (30 ml). The resulting solid was filtered through a pad of Celite and washed several times with THF. The oil obtained after evaporation of the solvent solidified on standing. The reaction mixture was purified by flash chromatography on silica gel using 5% CH₃OH(NH₃)/EtOAc as eluent, yielding 6.21 g (72%) of **62**. LC-MS: m/z = 125 (M+1).

Step 3:



MnO₂ (29 g, 334 mmol) was added, in one portion, at RT, to a suspension of 3-amino-4-hydroxymethyl pyridine (5.0 g, 40.3 mmol) in CHCl₃ (500 ml) with good stirring. After 2 days, the solid was filtered through a pad of Celite and washed with CHCl₃. Removal of the solvent using reduced pressure yielded 4.2 g (85%) of a yellow solid.



Step 4:



A dry solution of ethyl isonipecotate (12.5 g, 79.5 mmol) and the product of Step 3 (3.33 g, 27.3 mmol) in CH₂Cl₂ (400 ml) was stirred at RT for 1 h, then 60 g of activated 3A molecular sieves were added. The mixture was stirred for an additional 90 min, then NaHB(OAc)₃ (20 g, 96.4 mmol) was added at RT in one portion. After stirring for 3 days, the solid was filtered through a pad of Celite and washed with CH₂Cl₂. The solution was stirred for 15 min with saturated aqueous NaHCO₃ (100 ml), then separated from the aqueous layer. The organic layer was washed 2 more times with saturated aqueous NaHCO₃, then with brine and dried with anhydrous Na₂SO₄. After evaporation of the solvent, the resulting oil was purified by flash chromatography on silica gel using EtOAc:Hexanes:CH₃OH(NH₃) [50:45:5] as eluent. The procedure yielded 6.8 gr.(94%) of **64**. FAB-MS: m/z = 264 (M+1).

Step 5:

The product of Step 4 (4.75 g, 18.04 mmol) was stirred for 24 h at RT with LiOH monohydrate (1.51 g, 36 mmol) in CH₃OH (75 ml). Removal of the solvent using reduced pressure yielded the title compound as a white solid.


Preparation 6Step 1:

5 (Modified published procedure: G. Heinisch, E. Luszczak, and M. Pailer: *Monatshefte für Chemie*, 1973 (104), 1372.

65 (4.5 g, 47.8 mmoles), **66** (8.12g, 76.5 mmoles), and anhydrous ZnCl_2 were heated, under N_2 , in a dry apparatus, at a bath temperature of 160°C for 5 h. The resulting oil was purified by flash chromatography on silica gel using 30% Hexanes/EtOAc, yielding 5.92 grams (67%) of **67**.

Step 2:

OsO_4 (5.0 ml in t-butanol, 2.5% w/w) was added to **67** (5.9 g, 32.38 mmoles) dissolved in p-dioxane (87 ml) and water (29 ml). NaIO_4 (14.1 g, 65.92 mmoles) was added, with good stirring, in small portions, over a period of 6 h. The mixture was then diluted with p-dioxane and filtered. After removing most of the solvent under reduced pressure, the residue was taken in CH_2Cl_2 (600 ml) and dried over anhydrous Na_2SO_4 . After removal of the solvent, the mixture was purified by flash chromatography on silica gel using 5% $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ as eluent to obtain Preparation 6. Yield: 2.89 g (82%).


Preparation 7Step 1:

A solution of **68** (50 g, 0.41 mol) in CH_3OH (300 ml) was cooled to 0°C and carefully treated with NaBH_4 (20g, 0.53 mol in 6 batches) over 20 min. The reaction was then allowed to warm to 20°C and was stirred for 4 h. The mixture was again cooled to 0°C , carefully quenched with saturated aqueous NH_4Cl , and concentrated.


Flash chromatography (5–10% 7N $\text{NH}_3\text{-CH}_3\text{OH/CH}_2\text{Cl}_2$) provided **69** (31g, 62%) as a light yellow solid.

Step 2: A slurry of **69** (31 g, 0.25 mol) in CH_2Cl_2 (500 ml) was cooled to 0 °C and slowly treated with SOCl_2 (55ml, 0.74 mol over 30 min). The reaction was then stirred overnight at 20 °C. The material was concentrated, slurried in acetone, and then filtered. The resulting beige solid Preparation 7 was dried overnight in vacuo (38.4g, 52%, HCl salt).

Example 1



10 Step 1:




Preparation 1 (1.85 g, 5.43 mmol), Preparation 4E (1.0 g, 3.62 mmol), DEC (1.04 g, 5.43 mmol), HOBT (0.73 g, 5.43 mmol) and $\text{DMF/CH}_2\text{Cl}_2$ (1:1, 30 ml) were combined and stirred at RT overnight. The reaction was diluted with CH_2Cl_2 and washed with 0.5 N NaOH, water, brine, and dried (Na_2SO_4). Concentration gave a residue that was triturated with ether to give **11** (2.0 g, 93%). M.S. (M+H) = 594.

Step 2:

Compound **11** (0.18 g, 0.3 mmol) was stirred at RT in a 1:1 mixture of TFA: CH_2Cl_2 (4 ml) for 2.5 h. The solvent was removed in vacuo and the residue taken up in CH_2Cl_2 and washed with saturated aqueous NaHCO_3 . The organic layer was dried (Na_2SO_4) and concentrated to give a residue that was purified by flash column chromatography (SiO_2 , 15% CH_3OH in EtOAc) to give the title compound (0.14 g, 94%). MS (M+H) = 494.


Using a similar procedure and the appropriate starting material of the formula



25

, wherein Q is O or S, prepared as described in *J. Heterocyclic Chem.*,

30 (1993), p. 445, compounds of the following structure are prepared:




wherein Q and R are as defined in the table

Ex.	Q	R	MS (M+1)
1A	O		513
1B	O	-CH ₃	451
1C	S	-CH ₃	467
1D	S	-C(O)-O-CH ₂ CH ₃	525
1E	O	H	437

5







Example 2





To a solution of Example 1 (0.1 g, 0.2 mmol) in DMF (5 ml) at 0° C was added NaH (0.016 g, 0.4 mmol). The reaction was stirred at 0° C for 15 min and at RT for 45 min. Benzyl bromide (0.34 g, 0.2 mmol) was added and the reaction stirred for 2 h. The reaction was diluted with EtOAc and washed with saturated aqueous NH₄Cl, water and brine. The organic layer was dried (Na₂SO₄) and concentrated to give a residue that was purified on a flash column (10% CH₃OH in EtOAc) to give the title compound (0.02 g, 17%). MS (M+H) = 584.

In a similar manner to the procedure of Example 2, the following compounds were obtained:

Ex.	Starting Material	Product	Yield	MS (M+H)
A			67%	602

B			72%	585
C			15%	620
D			61%	585

Example 3Step 1:

5


A solution of **11** (0.2 g, 0.34 mmol) in $\text{CH}_2\text{Cl}_2/\text{DMF}$ (1:1, 10 ml) at 0 °C was treated with Et_3N (0.1 g) and dimethylsulfamoyl chloride (0.097 g, 0.68 mmol). The reaction was warmed to RT and stirred overnight. Additional dimethylsulfamoyl chloride and Et_3N was added and the reaction heated at 50 °C for 6 h. The reaction was cooled and concentrated, and the residue purified on a flash column (SiO_2 , EtOAc to 5% CH_3OH in EtOAc) to give **12** (0.08 g, 34%). MS ($\text{M}+\text{H}$) = 701.


10

Step 2:


In a manner similar to that described in Example 1, Step 2, **12** (0.08 g, 0.11 mmol) was converted to the title compound (0.06 g, 100%). MS ($\text{M}+\text{H}$) = 601.

15


Example 4

Step 1:


A solution of **13** (5.07 g, 35 mmol of HCl salt which was converted to the free base by treatment with NH_3 saturated CH_3OH) and **14** (4.25 g, 35 mmol) in EtOH (10 mol) was heated to 80 °C for 2 h. The reaction was cooled and the solvent removed in vacuo to give a yellow solid, which was washed with cold EtOH to give **15** (6.9 g, 94%). MS (M+H) = 212.

Step 2:

Compound **15** (1.86 g, 8.8 mmol) and polyphosphoric acid (30 g) were heated to 110 °C for 6 h. The reaction was cooled to RT and stirred overnight. The reaction was cooled to 0 °C, neutralized with 10% aqueous NaOH and extracted with EtOAc. The combined organic extracts were washed with water and brine and dried (Na_2SO_4) and concentrated to give **16** (1.1 g, 64%). MS (M+H) = 195.

Step 3:

To a solution of **16** (1.6 g, 8.24 mmol) in AcOH (30 ml) at 80 °C was added 4-piperidone hydrochloride (3.7 g, 23.9 mmol) and H_3PO_4 (10 ml). The reaction was stirred at this temperature for 72 h and at 100° C for 24 h. The reaction was cooled to RT and poured into ice/ NH_4OH and extracted with EtOAc. The combined organic layers were washed with water and brine, dried (Na_2SO_4) and concentrated. The residue was purified on a flash column (20% EtOAc in hexane to 10% $\text{CH}_3\text{OH}/\text{NH}_3$ in CH_2Cl_2) to give **17** (0.5 g, 44% based on recovered starting material). MS (M+H) = 276.


Step 4:

Compound **17** (0.5 g, 1.8 mmol), 10% Pd/C (0.05 g), and NH_4CHO_2 (0.92 g, 14.5 mmol) were combined in CH_3OH (20 ml) and heated to reflux overnight. The reaction was cooled, filtered through celite, and the filter cake washed with additional CH_3OH . The solvent was concentrated to give **18** (0.6 g, >100%) which was used without further purification. MS (M+H) = 278.

Step 5:


In a manner similar to that described in Example 1, steps 1 and 2, **18** (0.6 g, 2.2 mmol) was converted to the title compound (0.08 g, 72% over two steps). MS (M+H) = 495.

Example 5




In a manner similar to that described in Example 2, the compound of Example 4 (0.12 g, 0.24 mmol) was converted to the title compound (0.05 g, 36%). MS spectrum (M+H) = 586.

Example 6



Step 1:



















Compound **23** (0.08 g, 0.13 mmol), 3,5-difluorophenylboronic acid (0.04 g, 0.26 mmol), $\text{Cu}(\text{OAc})_2$ (0.005 g, 0.026 mmol), TEMPO (0.023 g, 0.143 mmol), pyridine (0.021 g, 0.26 mmol) and 3 Å molecular sieves (0.1 g) were combined in CH_2Cl_2 (10 ml) and heated to reflux overnight. The CH_2Cl_2 was removed in vacuo, DMF (5 ml) was added and the reaction heated to 70 °C for 7 h. The reaction was cooled to RT and stirred for 48 h. The solvent was removed and the residue purified using flash chromatography (SiO_2 , 3% CH_3OH in EtOAc) to give **24** (0.031 g, 33%). MS (M+H) = 725.



Step 2:



In a manner similar to that described in Example 1, Step 4, **24** (0.031 g) was converted to the title compound (0.02g). MS (M+H) = 625.

Using the appropriate starting material and the procedures of Examples 4 and 5, the following compounds were prepared:


Ex.	Product	MS (M+H)
6A		605
6B		513
6C		604
6D		623
6E		606
6F		608
6G		587

6H		620
6I		619
6J		479
6K		622
6L		509
6M		551
6N		496
6O		527
6P		618

6Q		436
6R		495

Example 7 and 7AStep 1:


A mixture of **25** (10 g, 51.2 mmol) and the piperidone HCl salt (8 g, 51.2 mmol) in AcOH (100 ml) and H₃PO₄ (40 ml of 1 M solution in water) was refluxed for 2 days. The reaction mixture was then concentrated in vacuo, partitioned between EtOAc (200 ml) and water (100 ml) and basified with KOH. The organic layer was isolated, washed with brine and dried with anhydrous Na₂SO₄. Concentration in vacuo provided crude **26** which was purified by flash chromatography on a silica gel column, eluting with 5% CH₃OH in CH₂Cl₂ (with 0.5 % saturated aqueous NH₄OH). Pure **26** was obtained (2.5 g, 18% yield) as a light brown solid.

Step 2:

26 (1.15g) was coupled with Preparation 1 with EDC under standard amide-coupling conditions. After work up, flash chromatography over silica gel using 5% CH₃OH in CH₂Cl₂ with 0.5% saturated aqueous NH₄OH as eluant provided pure **28**


(1.5 g, 60% yield). HCl deprotection of the pyridine amine provided, quantitatively, the title compound. MS (ES) $m/e = 488$ (MH^+).

Starting from Preparation 4B, the following compound was made in a similar manner to Example 7:




Ex. 7B: MS (ES) $m/e = 430$ (MH^+).

Example 8




Step 1:




10 26 (1.4 g) was dissolved in EtOH, treated with $Pd(OH)_2$ (0.1 g), acidified with HCl (12N, 1 ml) and stirred under a hydrogen atmosphere supplied by a balloon for 60 h. The reaction mixture was then filtered through celite and concentrated to provide 29.

Step 2:




15 29 (0.8 g) was coupled with Preparation 1 under standard amide-coupling conditions to provide 30 (1.1 g, 64% yield), as an off-white solid after flash chromatography over silica gel (5% CH_3OH in CH_2Cl_2 with 0.5% saturated aqueous NH_4OH). HCl deprotection of the pyridine amine provided, quantitatively, the title compound as an off-white solid. MS (ES) $m/e = 490$ (MH^+).

20

Example 9

Starting from Preparation 4A, the title compound was made in a manner similar to Example 7. MS (ES) $m/e = 418$ (MH^+).


Examples 10, 10A, 10B and 10C

A solution of isopropylamine (59 mg, 1 mmol) in toluene (10 ml), at RT was treated with trimethylaluminum (2.0 M solution in toluene, 2 mmol) and stirred at RT for 30 min, whereupon compound 28 (0.21 g, 0.35 mmol) was added. The reaction mixture was heated to 80 °C, stirred overnight at that temperature and then cooled to RT and carefully quenched with saturated aqueous Na_2SO_4 . After the bubbling of hydrogen had ceased, solid Na_2SO_4 was added to absorb water. Filtration through a filter paper and concentration in vacuo provided crude Example 10 and 33. The entire product mixture was treated with HCl (1.5 N CH_3OH /dioxane) and stirred at 60 °C for 2 h. The mixture was then concentrated in vacuo and run through a silica gel flash column (10% CH_3OH in CH_2Cl_2 with 0.5% saturated aqueous NH_4OH). Two products were obtained:

Example 10 (45 mg, off-white solid) MS (ES) $m/e = 586$ (MH^+); and


Example 10A (7 mg, light-orange solid) MS (ES) $m/e = 501$ (MH^+).

In a similar manner, using **28** and commercially available 1-methyl-4-(methylamino)piperidine, Example 10B was prepared:




Ex. 10B: MS (ES) $m/e = 724$ (MH^+).

In a similar manner, using **28** (only the *t*-butyl carbamate portion of the molecule, and not the ester, reacted with the amine) and commercially available 2-aminopyridine, Example 10C was prepared:




Ex. 10C: MS (ES) $m/e = 608$ (MH^+).

Examples 11 and 11A





A solution of **32** (0.2 g, 0.38 mmol) in DMF (5 ml) at RT was treated with NaH (0.12 g, 60% dispersion in mineral oil) and stirred for 30 min. 3-Picolyl chloride (0.38 mmol, HCl salt) was then added and the resulting mixture stirred overnight. CH₂Cl₂ (20 ml) was then added to solubilize the substrate and the mixture stirred over the weekend. The reaction was then quenched with saturated aqueous Na₂SO₄ until the bubbling of hydrogen ceased and dried with solid Na₂SO₄, filtered and concentrated in vacuo. The crude product mixture was taken up in 2 N HCl (CH₃OH/dioxane), stirred for 2 h at 60 °C and concentrated in vacuo. Silica gel prep plate separation (10% CH₃OH in CH₂Cl₂ with 0.3% saturated aqueous NH₄OH) afforded Example 11A (40 mg) as an off-white solid (MS (ES) m/e = 509 (MH⁺)) and Example 11 (22 mg) as an off-white solid (MS (ES) m/e = 600 (MH⁺)).


Using **32** and 2-picolyl chloride in a procedure similar to Example 11, the following compound was prepared:



Ex. 11B: MS (ES) $m/e = 509$ (MH^+).


Example 12






A solution of **30** (1.1 g) in dioxane/H₂O (12:1, 25 ml) was treated with LiOH.H₂O (0.3 g) and stirred overnight at 70 °C. Concentration in vacuo provided crude **35** that was used in the next step without further purification. **35** (0.27 g) was coupled with isopropyl amine, using EDC under standard amide-coupling conditions, to provide crude **36**. Separation on a silica gel prep plate (10 % CH₃OH in CH₂Cl₂ with 0.25 % saturated aqueous NH₄OH) provided pure **36**. Cleavage of the BOC-protecting group with HCl provided the title compound (90 mg, HCl salt) as an off-white solid. MS (ES) m/e = 503 (MH⁺).

Using the appropriate amine in the procedure of Example 12, the compounds of the following structure were prepared:




wherein R is as defined in the table

Ex.	R	Physical Data
12A	-C(O)-NH-CH ₃	MS (ES) m/e = 475 (MH ⁺)
12B	-C(O)-NH-CH ₂ CH ₃	MS (ES) m/e = 489 (MH ⁺)
12C		MS (ES) m/e = 616 (MH ⁺)
12D		MS (ES) m/e = 572 (MH ⁺)

Example 13


Example 13 was prepared using Preparation 4B and 2-picolyl chloride in a procedure similar to Example 12. MS (ES) $m/e = 521$ (MH^+).


- 5 Using Preparation 4B or Preparation 4C and the appropriate halide, the following compounds were prepared in a manner similar to Example 13:



wherein R is as defined in the table

Ex.	R ⁸	Optional Double Bond	Physical Data
13A		present	MS (ES) $m/e = 520$ (MH^+)
13B	CF ₃ -(CH ₂) ₃ -	present	MS (ES) $m/e = 540$ (MH^+)
13C	CH ₃ -CH ₂ -	present	MS (ES) $m/e = 458$ (MH^+)
13D		absent	MS (ES) $m/e = 523$ (MH^+)
13E	H	absent	MS (ES) $m/e = 432$ (MH^+)
13F		absent	MS (ES) $m/e = 523$ (MH^+)

Example 14



A solution of Preparation 4 (4.5 g, 22.6 mmol) in CH₃OH (100 ml) was treated with BOC₂O (9.9 g, 45.2 mmol) and stirred overnight. Concentration to dryness and purification by flash chromatography on silica gel using 7% NH₃ saturated CH₃OH in CH₂Cl₂ provided clean **37**. A solution of **37** (2.5 g, 8.4 mmol) in DMF (15 ml) at 0 °C was treated with 3 mole equivalents of NaH and stirred for ten minutes at 0 °C and 45 min at RT. One mole equivalent of CH₃I was added and the mixture stirred overnight. The mixture was then concentrated and partitioned between NH₄Cl saturated water (100 ml) and EtOAc (100 ml). The organic layer was isolated and concentrated to provide crude **38** (2.3 g), which was converted to **39** in similar manner to **29**.


All of **39** was taken up in CH₂Cl₂ (50 ml) and treated successively with silica gel (15 ml), and *N*-bromosuccinimide (0.3 g, 1.6 mmol) in the dark and stirred at RT for 1.5 h. Filtration through a fritted funnel and concentration provided crude **40** which was purified on a silica gel flash column, eluting with 20 % EtOAc in hexane.

A mixture of **40** (0.45 g, 1.14 mmol), 3-fluorophenyl boronic acid (176 mg, 1.26 mmol), Ba(OH)₂·8H₂O (0.54 g, 1.7 mmol) and tetrakis(triphenylphosphine)-palladium(0) (26 mg, 0.022 mmol) in dimethoxyethane/H₂O (2:1, 100 ml) was refluxed for 4 h. and then concentrated in vacuo. The crude product mixture was partitioned between CH₂Cl₂ (100 ml) and water (75 ml). The organic layer was isolated and dried with MgSO₄. Separation on silica gel prep plates using hexane/EtOAc (9:1) as eluant provided pure **41** (0.4 g). HCl cleavage of the BOC-protecting group gave amine **42**.

that was converted to the title compound in a similar manner to Example 7.


MS (ES) $m/e = 526$ (MH^+).

Example 15




With the piperidine amine protected with a BOC group, the indole nitrogen of 29 was deprotected with NaHMDS in DMF and alkylated with CH_3I . HCl-deprotection of the resulting intermediate provided 43. Standard amide-coupling of 43 and Preparation 3A gave the title compound. MS (ES) $m/e = 505$ (MH^+).

Example 16



The title compound was obtained by standard amide-coupling of Preparation 4B to Preparation 3. MS (ES) $m/e = 431$ (MH^+).


Example 17



A solution of 44 (225 mg, 0.42 mmol), obtained by amide-coupling of Preparation 4C and 28 in DMF (3 ml) at 0°C was treated with NaH (51 mg, 1.3 mmol) and stirred at 0°C for 10 min and at RT for 30 min. CH_3I (0.43 mmol) was then


- added and the resulting mixture stirred overnight at RT. The reaction mixture was then concentrated in vacuo and partitioned between saturated aqueous NH_4Cl (30 ml) and CH_2Cl_2 (50 ml). Concentration and flash chromatography on silica gel (2 % NH_3 saturated CH_3OH in CH_2Cl_2) provided the *N,N'*-dimethyl amine precursor of the title compound (48 mg). Cleavage of the BOC group with TFA provided the title compound. MS (ES) $m/e = 460$ (MH^+).

Example 18




- 10 A mixture of 45 (2.1 g, 10 mmol), BOC-piperidone (3.4 g, 17 mmol) and KOH (0.28 g, 5 mmol) in CH_3OH (150 ml) was refluxed for eight days. The reaction mixture was then concentrated in vacuo, partitioned between water (50 ml) and CH_2Cl_2 (100 ml), and acidified with AcOH. The organic layer was isolated and concentrated to provide crude 46. Cleavage of the BOC group with HCl provided 47.
- 15 Standard amide-coupling of 47 to 48 (Prep. 3B) using EDC provided the title compound. MS (ES) $m/e = 526$ (MH^+).

Example 19




Step 1:


- 42 -



4-Fluoro aniline (13.3 g, 120 mmol) and 1-benzyl-4-piperidone (18.9 g, 100 mmol) were stirred at RT, under N₂, in dry CH₂Cl₂ (120 ml) for 4 h. NaBH(OAc)₃ (32g, 151 mmol) was then added and the mixture stirred at RT for 60 h. After dilution with CH₂Cl₂ (100 ml), the solution was stirred for 30 min. with saturated aqueous NaHCO₃. The aqueous layer was separated and extracted with CH₂Cl₂. The combined organic solutions were washed with brine and dried over anhydrous Na₂SO₄. The reaction mixture was purified by flash chromatography on silica gel using 30% EtOAc/Hexanes as eluent, followed by 50% EtOAc/Hexanes, then by 20% Hexanes/EtOAc. Yield: 22.13g. (78%). MS: m/z = 285 (M+1).

Step 2:


4 M HCl in p-dioxane (20 ml, 80 mmol) was added to a precooled solution (ice bath) of 49 (4.06 g, 14.28 mmol) in CH₂Cl₂ (80 ml). To the resulting mixture were added, dropwise with good stirring, NaNO₂ (1.97 g, 28.6 mmol) dissolved in water (10 ml). After the addition, the mixture was stirred in the ice bath for another 3 h, then made basic with saturated aqueous NaHCO₃ and stirred at RT for an additional 30 min. After separating the organic layer, the aqueous layer was extracted with CH₂Cl₂. The organic layers were combined, washed with brine and dried over anhydrous Na₂SO₄. The reaction mixture was purified by flash chromatography on silica gel using 20% EtOAc/Hexanes as eluent. Yield: 3.0 g (67%). MS: m/z = 314 (M+1).

Step 3:

A dry THF solution (25 ml) of 50 (3.0 g, 9.6 mmol) was added, slowly, dropwise, under N₂ to a pre-cooled (ice bath) slurry of LiAlH₄ (0.76 g, 20 mmol) in dry THF (30 ml). After the addition, the mixture was allowed to warm up and was stirred at RT for


15 h. The mixture was then cooled again in an ice bath and the reaction was quenched by adding, dropwise under N_2 , water (1.0 ml), then aqueous NaOH (1.0 ml of 15%), followed by 3.0 ml of water. The resulting solid was filtered through a pad of "Celite" and washed several times with THF. The reaction mixture was purified by
 5 flash chromatography on silica gel using 50% EtOAc/Hexanes as eluent. Yield: 1.95 g. (66%). MS: $m/z = 300$ ($M+1$).

Step 4:




Neat 2-acetyl pyridine (0.73 g, 6.0 mmol) and 51 (1.0 g, 3.34 mmol) were
 10 heated in a pressure tube at a bath temperature of 140 °C for 19 h. The reaction mixture was purified by flash chromatography on silica gel using 20% EtOAc/Hexanes as eluent. Yield: 1.09 g. (81%). MS: $m/z = 403$ ($M+1$).

Step 5:



15 Trifluoroacetic anhydride (0.37 ml, 2.6 mmol) was added dropwise, under N_2 , to a dry THF solution of 52 (0.816 g, 2.03 mmol) precooled in an ice bath. After the addition, the solution was stirred at 0 °C for 90 min, then heated to reflux for 5 h. After removing the solvent using reduced pressure, the residue was treated with saturated aqueous $NaHCO_3$ and extracted with CH_2Cl_2 . The organic extracts were
 20 combined, washed with brine and dried over anhydrous Na_2SO_4 . The reaction mixture was purified by flash chromatography on silica gel using 15% EtOAc/Hexanes as eluent. Yield: 0.56 g. (71%). MS: $m/z = 386$ ($M+1$).

Step 6:




1-chloroethyl chloroformate (0.42 g, 3.9 mmol) was added, under N₂, at RT, to a solution of **53** (0.5 g, 1.3 mmol) dissolved in 1,2-dichloroethane (10 ml). The solution was then refluxed for 2 h, cooled to RT, CH₃OH (5.0 ml) was added, and the solution refluxed again for 90 min. After removing the solvent with reduced pressure, the reaction mixture was purified by preparative TLC using 10% CH₃OH(NH₃)/EtOAc as eluent. Yield: 0.23 g. (59%). MS: m/z = 296 (M+1).


Step 7:

54 (92 mg, 1.58 mmol), Preparation **5** (113 mg, 0.47 mmol), EDC.HCl (0.105 mg, 0.55 mmol), and HOBT (74 mg, 0.55 mmol) were stirred at RT in dry DMF (2.0 ml) for 2 days. The reaction was quenched with 0.5 N aqueous NaOH (5.0 ml), then the solution was extracted with CH₂Cl₂. The combined extracts were washed with brine and dried over anhydrous Na₂SO₄. The title compound was isolated by preparative TLC on silica gel using EtOAc:Hexanes:CH₃OH(NH₃) (70:25:5) as eluent. Yield: 82 mg. (51%). MS: m/z = 513 (M+1).


Using a similar procedure, the following compounds were prepared:




Ex. 19A: MS: m/z = 495 (M+1).




Ex. 19B: MS: m/z = 481 (M+1).



Ex. 19C: MS: m/z = 481 (M+1).




Ex. 19D: MS: m/z = 499 (M+1).



Ex. 19E: MS: $m/z = 517 (M+1)$.

Using the appropriate starting materials and the appropriate procedures shown above, the following compounds were made:




5 wherein R, R⁸ and R² are as defined in the table:

Ex.	R	R ⁸	Y	R ²	Data MS (M+H)
20			-C(O)-		674
21			-C(O)-		710
22			-C(O)-		810
23		H	bond		466
24		CH ₃ CH ₂ -	-C(O)-		551
25			-C(O)-		678

26			-C(O)-		766
27			-C(O)-		574
28			-C(O)-		607
29		H	-C(O)-		520


Example 30




- 5 A mixture of indoline carboxylic acid **55** (10 g, 6.1 mmol) and amine **56**, HCl salt (5.97 g, 6.1 mmol) in DMF (100 ml) was treated with EDC (9.15 mmol), HOBT (6.1 mmol) and diisopropylethylamine (2 ml) at RT and stirred overnight. The reaction mixture was then concentrated under vacuum, partitioned between water (100 ml) and CH_2Cl_2 (100 ml) and basified with NaHCO_3 . The organic layer was isolated,
- 10 dried and concentrated to provide crude **57**. All of **57** was dissolved in AcOH (100 ml) and treated successively with BOC-piperidone (6.1 mmol) and $\text{Na}(\text{OAc})_3\text{BH}$ (12.2 mmol) and stirred at RT overnight. The reaction mixture was then partitioned between water (300 ml) and CH_2Cl_2 (200 ml) and basified with NaOH. The organic layer was isolated, washed with brine and dried with crystalline Na_2SO_4 .

Concentration under vacuum provided crude **58**, quantitatively, as an off white solid. HCl cleavage of the BOC group provided **59**. Using standard amide coupling techniques as described above, **59** was converted to the title compound. MS (M+1) = 508.


- 5 Using the appropriate indolene starting materials in a similar procedure, the following compounds were prepared:



Ex. 31: MS (M+1) = 420



Ex. 32: MS (M+1) = 439



Ex. 33: MS (M+1)= 477

10

General Procedure for H₃-Receptor Binding Assay

The source of the H₃ receptors in this experiment was guinea pig brain. The animals weighed 400-600 g. The brain tissue was homogenized with a solution of 50 mM Tris, pH 7.5. The final concentration of tissue in the homogenization buffer was 10% w/v. The homogenates were centrifuged at 1,000 x g for 10 min. in order to remove clumps of tissue and debris. The resulting supernatants were then centrifuged at 50,000 x g for 20 min. in order to sediment the membranes, which were next washed three times in homogenization buffer (50,000 x g for 20 min. each). The membranes were frozen and stored at -70°C until needed.

20 All compounds to be tested were dissolved in DMSO and then diluted into the binding buffer (50 mM Tris, pH 7.5) such that the final concentration was 2 µg/ml with 0.1% DMSO. Membranes were then added (400 µg of protein) to the reaction tubes. The reaction was started by the addition of 3 nM [³H]R-α-methyl histamine (8.8 Ci/mmol) or 3 nM [³H]N^α-methyl histamine (80 Ci/mmol) and continued under incubation at 30°C for 30 min. Bound ligand was separated from unbound ligand by

25

filtration, and the amount of radioactive ligand bound to the membranes was quantitated by liquid scintillation spectrometry. All incubations were performed in duplicate and the standard error was always less than 10%. Compounds that inhibited more than 70% of the specific binding of radioactive ligand to the receptor
5 were serially diluted to determine a K_i (nM).

Compounds of formula I have a K_i within the range of about 1 to about 1000 nM. Preferred compounds of formula I have a K_i within the range of about 1 to about 100 nM. More preferred compounds of formula I have a K_i within the range of about 1 to about 20 nM. The compound of Example 5 has a K_i of 1.50 nM.

10 In this specification, the term "at least one compound of formula I" means that one to three different compounds of formula I may be used in a pharmaceutical composition or method of treatment. Preferably one compound of formula I is used. Similarly, "at least one H_1 receptor antagonist" means that one to three different H_1 antagonists may be used in a pharmaceutical composition or method of treatment.
15 Preferably, one H_1 antagonist is used.

For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from
20 about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), *The Science and Practice of Pharmacy*, 20th Edition, (2000), Lippincott Williams & Wilkins,
25 Baltimore, MD.

Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and
30 emulsions. Liquid form preparations may also include solutions for intranasal administration.

Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

5 The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.

Preferably the compound is administered orally.

10 Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.

The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 150 mg, preferably from about 1 mg to about 75
15 mg, more preferably from about 1 mg to about 50 mg, according to the particular application.

The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For
20 convenience, the total daily dosage may be divided and administered in portions during the day as required.

The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and
25 size of the patient as well as severity of the symptoms being treated. A typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 300 mg/day, preferably 1 mg/day to 75 mg/day, in two to four divided doses.

30 When the invention comprises a combination of H₃ antagonist and H₁ antagonist compounds, the two active components may be co-administered simultaneously or sequentially, or a single pharmaceutical composition comprising a H₃ antagonist and an H₁ antagonist in a pharmaceutically acceptable carrier can be administered. The components of the combination can be administered individually or together in any conventional dosage form such as capsule, tablet, powder, cachet,

suspension, solution, suppository, nasal spray, etc. The dosage of the H₁ antagonist can be determined from published material, and may range from 1 to 1000 mg per dose. When used in combination, the dosage levels of the individual components are preferably lower than the recommended individual dosages because of the


5 advantageous effect of the combination.

When separate H₃ and H₁ antagonist pharmaceutical compositions are to be administered, they can be provided in a kit comprising in a single package, one container comprising an H₃ antagonist in a pharmaceutically acceptable carrier, and a separate container comprising an H₁ antagonist in a pharmaceutically acceptable
10 carrier, with the H₃ and H₁ antagonists being present in amounts such that the combination is therapeutically effective. A kit is advantageous for administering a combination when, for example, the components must be administered at different time intervals or when they are in different dosage forms.

While the present invention has been described in conjunction with the specific
15 embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

WHAT IS CLAIMED IS:

1. A compound represented by the structural formula



- 5 or a pharmaceutically acceptable salt or solvate thereof, wherein:

a is 0 to 3;

b is 0 to 3;

n is 1, 2 or 3;

p is 1, 2 or 3;

10 r is 0, 1, 2, or 3;

X is a bond or C₁-C₆ alkylene;

M¹ is CH or N;

M² is C(R³) or N;

with the provisos that when M² is N, p is not 1; and that when r is 0, M² is


15 C(R³); and that the sum of p and r is 1 to 4;


Y is -C(=O)-, -C(=S)-, -(CH₂)_q-, -NR⁴C(=O)-, -C(=O)NR⁴-, -C(=O)CH₂-, -SO₁₋₂-,
-C(=N-CN)-NH- or -NH-C(=N-CN)-; with the provisos that when M¹ is N, Y is not
-NR⁴C(=O)- or -NH-C(=N-CN)-; and when M² is N, Y is not -C(=O)NR⁴- or
-C(=N-CN)-NH-;

20 q is 1 to 5, provided that when M¹ and M² are both N, q is not 1;

Z is a bond, C₁-C₆ alkylene, C₂-C₆ alkenylene, -C(=O)-, -CH(CN)- or
-CH₂C(=O)NR⁴-;

R¹ is





Q is $-N(R^8)-$, $-S-$ or $-O-$;

k is 0, 1, 2, 3 or 4;

k1 is 0, 1, 2 or 3;


5 k2 is 0, 1 or 2;

the dotted line represents an optional double bond;

R and R^7 are independently selected from the group consisting of H, C_1-C_6 alkyl, halo(C_1-C_6)alkyl-, C_1-C_6 alkoxy, (C_1-C_6)alkoxy-(C_1-C_6)alkyl-, (C_1-C_6)-alkoxy-
 (C1-C6)alkoxy, (C_1-C_6)alkoxy-(C_1-C_6)alkyl-SO₀₋₂, R^{32} -aryl(C_1-C_6)alkoxy-, R^{32} -aryl-
 10 (C1-C6)alkyl-, R^{32} -aryl, R^{32} -aryloxy, R^{32} -heteroaryl, (C_3-C_6)cycloalkyl, (C_3-C_6)cycloalkyl-
 (C1-C6)alkyl, (C_3-C_6)cycloalkyl-(C_1-C_6)alkoxy, (C_3-C_6)cycloalkyl-oxy-, R^{37} -heterocyclo-
 alkyl, $N(R^{30})(R^{31})-(C_1-C_6)$ alkyl-, $-N(R^{30})(R^{31})$, $-NH-(C_1-C_6)$ alkyl-O-(C_1-C_6)alkyl,
 $-NHC(O)NH(R^{29})$; $R^{22}-S(O)_{0-2}$, halo(C_1-C_6)alkyl-S(O)₀₋₂-, $N(R^{30})(R^{31})-(C_1-C_6)$ alkyl-
 S(O)₀₋₂-, benzoyl, (C_1-C_6)alkoxy-carbonyl, R^{37} -heterocycloalkyl-N(R^{29})-C(O)-, (C_1 -
 15 C6)alkyl-N(R^{29})-C(O)-, (C_1-C_6)alkyl-N(C_1-C_6 alkoxy)-C(O)-, $-C(=NOR^{36})R^{36}$ and
 $-NHC(O)R^{29}$; and when the optional double bond is not present, R^7 can be OH;

R^8 is H, C_1-C_6 alkyl, halo(C_1-C_6)alkyl-, (C_1-C_6)alkoxy-(C_2-C_6)alkyl-, R^{32} -aryl(C_1 -
 C6)alkyl-, R^{32} -aryl, R^{32} -heteroaryl, R^{32} -heteroaryl(C_1-C_6)alkyl-, (C_3-C_6)cycloalkyl, (C_3 -
 C6)cycloalkyl-(C_1-C_6)alkyl, R^{37} -heterocycloalkyl, R^{37} -heterocycloalkyl(C_1-C_6)alkyl,
 20 $N(R^{30})(R^{31})-(C_2-C_6)$ alkyl-, $R^{22}-S(O)_2$ -, halo(C_1-C_6)alkyl-S(O)₂-, $R^{22}-S(O)_{0-1}-(C_2-C_6)$ alkyl-,
 halo(C_1-C_6)alkyl-S(O)_{0-1}-(C_2-C_6)alkyl-, (C_1-C_6)alkyl-N(R^{29})-SO₂-, or R^{32} -heteroaryl-SO₂;}

R^2 is a six-membered heteroaryl ring having 1 or 2 heteroatoms independently
 selected from N or N-O, with the remaining ring atoms being carbon; a five-
 membered heteroaryl ring having 1, 2, 3 or 4 heteroatoms independently selected
 25 from N, O or S, with the remaining ring atoms being carbon; R^{32} -quinolyl; R^{32} -aryl;



or heterocycloalkyl; wherein said six-membered heteroaryl ring or said five-membered
 heteroaryl ring is optionally substituted by R^6 ;

R^3 is H, halogen, C_1 - C_6 alkyl, -OH or (C_1-C_6) alkoxy;

R^4 is independently selected from the group consisting of hydrogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, (C_3-C_6) cycloalkyl(C_1 - C_6)alkyl, R^{33} -aryl, R^{33} -aryl(C_1 - C_6)alkyl, and R^{32} -heteroaryl;

5 R^5 is hydrogen, C_1 - C_6 alkyl, $-C(O)R^{20}$, $-C(O)_2R^{20}$, $-C(O)N(R^{20})_2$, R^{33} -aryl(C_1 - C_6)alkyl or (C_1-C_6) alkyl- SO_2 -;

R^6 is 1 to 3 substituents independently selected from the group consisting of -OH, halogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, $-CF_3$, $-NR^4R^5$, $-(C_1-C_6)$ alkyl- NR^4R^5 , phenyl, R^{33} -phenyl, NO_2 , $-CO_2R^4$, $-CON(R^4)_2$, $-NHC(O)N(R^4)_2$, R^{32} -heteroaryl- SO_2 -NH-,
10 R^{32} -aryl- (C_1-C_6) alkyl-NH-, R^{32} -heteroaryl- (C_1-C_6) alkyl-NH-, R^{32} -heteroaryl-NH- $C(O)$ -NH-, R^{37} -heterocycloalkyl- $N(R^{29})$ - $C(O)$ - and R^{37} -heterocycloalkyl- $N(R^{29})$ - $C(O)$ -NH-;

R^{12} is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxyl, C_1 - C_6 alkoxy, or fluoro, provided that when R^{12} is hydroxy or fluoro, then R^{12}
15 is not bound to a carbon adjacent to a nitrogen; or R^{12} forms a C_1 to C_2 alkyl bridge from one ring carbon to another ring carbon;

R^{13} is independently selected from the group consisting of C_1 - C_6 alkyl, hydroxyl, C_1 - C_6 alkoxy, or fluoro, provided that when R^{13} is hydroxy or fluoro then R^{13} is not bound to a carbon adjacent to a nitrogen; or forms a C_1 to C_2 alkyl bridge from
20 one ring carbon to another ring carbon; or R^{13} is =O;

R^{20} is independently selected from the group consisting of hydrogen, C_1 - C_6 alkyl, or aryl, wherein said aryl group is optionally substituted with from 1 to 3 groups independently selected from halogen, $-CF_3$, $-OCF_3$, hydroxyl, or methoxy; or when two R^{20} groups are present, said two R^{20} groups taken together with the nitrogen to which
25 they are bound can form a five or six membered heterocyclic ring;

R^{22} is C_1 - C_6 alkyl, R^{34} -aryl or heterocycloalkyl;

R^{24} is H, C_1 - C_6 alkyl, $-SO_2R^{22}$ or R^{34} -aryl;

R^{25} is independently selected from the group consisting of C_1 - C_6 alkyl, halogen, CN, $-CF_3$, -OH, C_1 - C_6 alkoxy, (C_1-C_6) alkyl- $C(O)$ -, aryl- $C(O)$ -, $N(R^4)(R^5)$ - $C(O)$ -,
30 $N(R^4)(R^5)$ - $S(O)_{1-2}$ -, halo- (C_1-C_6) alkyl- or halo- (C_1-C_6) alkoxy- (C_1-C_6) alkyl-;

R^{29} is H, C_1 - C_6 alkyl, R^{35} -aryl or R^{35} -aryl(C_1 - C_6)alkyl-;

R^{30} is H, C_1 - C_6 alkyl-, R^{35} -aryl or R^{35} -aryl(C_1 - C_6)alkyl-;

R^{31} is H, C_1 - C_6 alkyl-, R^{35} -aryl, R^{35} -aryl(C_1 - C_6)alkyl-, (C_1-C_6) alkyl- $C(O)$ -, R^{35} -aryl- $C(O)$ -, $N(R^4)(R^5)$ - $C(O)$ -, (C_1-C_6) alkyl- $S(O)_2$ - or R^{35} -aryl- $S(O)_2$ -;

or R^{30} and R^{31} together are $-(CH_2)_{4-5}-$, $-(CH_2)_2-O-(CH_2)_2-$ or $-(CH_2)_2-N(R^{29})-(CH_2)_2-$ and form a ring with the nitrogen to which they are attached;

R^{32} is 1 to 3 substituents independently selected from the group consisting of H, -OH, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, R^{35} -aryl-O-, $-SR^{22}$, $-CF_3$, $-OCF_3$, $-OCHF_2$,
 5 $-NR^4R^5$, phenyl, R^{33} -phenyl, $-NO_2$, $-CO_2R^4$, $-CON(R^4)_2$, $-S(O)_2R^{22}$, $-S(O)_2N(R^{20})_2$,
 $-N(R^{24})S(O)_2R^{22}$, -CN, hydroxy- (C_1-C_6) alkyl-, $-OCH_2CH_2OR^{22}$, and R^{35} -aryl(C_1-C_6)-alkyl-O-, wherein said aryl group is optionally substituted with 1 to 3 independently selected halogens;

R^{33} is 1 to 3 substituents independently selected from the group consisting of
 10 C_1-C_6 alkyl, halogen, -CN, $-NO_2$, $-OCHF_2$ and $-O-(C_1-C_6)$ alkyl;

R^{34} is 1 to 3 substituents independently selected from the group consisting of H, halogen, $-CF_3$, $-OCF_3$, -OH and $-OCH_3$.

R^{35} is 1 to 3 substituents independently selected from the group consisting of hydrogen, halo, C_1-C_6 alkyl, hydroxy, C_1-C_6 alkoxy, phenoxy, $-CF_3$, $-N(R^{36})_2$, $-COOR^{20}$
 15 and $-NO_2$;

R^{36} is independently selected from the group consisting of H and C_1-C_6 alkyl;
 and

R^{37} is independently selected from the group consisting of H, C_1-C_6 alkyl and (C_1-C_6) alkoxycarbonyl.

20 2. A compound of claim 1 wherein M^1 is N, a is 0, n is 2, and the optional double bond in the ring containing M^1 is not present.


25 3. A compound of claim 1 wherein M^2 is $C(R^3)$ wherein R^3 is hydrogen or halogen, b is 0; r is 1 and p is 2.

4. A compound of claim 1 wherein Y is $-C(O)-$.


30 5. A compound of claim 1 wherein Z is straight or branched C_1-C_3 alkyl.

6. A compound of claim 1 wherein R^2 is a six-membered heteroaryl ring, optionally substituted with one R^6 substituent.

7. A compound of claim 1 wherein R^1 is











8. A compound of claim 7 wherein R is H, alkyl, R^{32} -aryl, R^{32} -heteroaryl, (C₁-C₆)alkoxy-carbonyl or (C₁-C₆)alkyl-N(R²⁹)-C(O)-.
- 5 9. A compound of claim 8 wherein R is R^{32} -phenyl or R^{32} -pyridyl.
10. A compound of claim 7 wherein R⁷ is hydrogen; R⁸ is H, R^{32} -aryl(C₁-C₆)alkyl-, R^{32} -heteroaryl(C₁-C₆)alkyl-, R^{32} -aryl, R^{32} -heteroaryl, (C₁-C₆)alkyl-N(R²⁹)-SO₂- or R^{37} -heterocycloalkyl(C₁-C₆)alkyl-; R²⁵ is H, halogen or -CF₃; and k is 0 or 1.
- 10 11. A compound of claim 10 wherein R⁸ is H, R^{32} -benzyl, R^{32} -pyridylmethyl, piperidinoethyl or (C₁-C₆)alkyl-N(R²⁹)-SO₂- wherein R²⁹ is H or C₁-C₆ alkyl.
- 15 12. A compound of claim 1 selected from the group consisting of compounds of the formula



wherein R, R⁸, R²⁵ and R² are as defined in the table:

R	R ⁸	R ²⁵	R ²
	(CH ₃) ₂ N-SO ₂ -	H	
		H	
CH ₃ CH ₂ -O-C(O)-	H	H	
CH ₃ -NH-C(O)-	H	H	
	H	H	

	H	F	
		H	
		H	

13. A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically effective carrier.

- 5 14. The use of a compound of claim 1 for the preparation of a medicament for the treatment of allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, obesity, sleeping disorders, disturbances of the central nervous system, attention deficit hyperactivity disorder, hypo and hyperactivity
10 of the central nervous system, Alzheimer's disease, schizophrenia, and migraine.

15. A pharmaceutical composition comprising an effective amount of a compound of claim 1, and an effective amount of H₁ receptor antagonist, and a pharmaceutically effective carrier.

15

16. The use of a compound of claim 1 for the preparation of a medicament for use in combination with an H₁ receptor antagonist for treating allergy, allergy-induced airway responses, and congestion.

- 20 17. The use of claim 16 wherein said H₁ receptor antagonist is selected from: astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, diphenhydramine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine,
25 levocabastine, meclizine, mizolastine, mequitazine, mianserin, noberastine, norastemizole, picumast, pyrilamine, promethazine, terfenadine, tripeleonnamine, temelastine, trimeprazine or triprolidine.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/19619

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/14 C07D405/14 C07D409/14 C07D471/04 A61K31/445
 A61P25/06 A61P25/18 A61P25/28 A61P25/20 A61P27/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 02 32893 A (SCHERING CORP) 25 April 2002 (2002-04-25) cited in the application table 1, compounds 232, 244, 247; table 2, compound 303 claims 1,34	1-16
Y	WO 02 36589 A (ALMIRALL PRODESFARMA SA ;PAGES SANTACANA LLUIS (ES); PUIG DURAN CA) 10 May 2002 (2002-05-10) Table 2, compounds 62-64 claims 1,13-15	1-16
P,Y	WO 02 072570 A (SCHERING CORP ;PHARMACOPEIA INC (US)) 19 September 2002 (2002-09-19) the whole document	1-16
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

4 September 2003

Date of mailing of the international search report

15/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Schuemacher, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/19619

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	WO 02 072093 A (SCHERING CORP) 19 September 2002 (2002-09-19) claims 1,2 -----	1-16

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claim 1 relates to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds with $a=b=0$; $n=p=2$; $r=1$, M1 is N, M2 is C; Y is $-C(=O)-$, $-C(=S)-$, $-CH_2-$ (this is equivalent to the compounds of claims 2 and 3) as well as the compounds prepared in the examples and closely related homologous compounds .

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/19619

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/19619

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0232893	A	25-04-2002	AU 1535502 A	29-04-2002
			BR 0114754 A	01-07-2003
			CA 2424664 A1	25-04-2002
			EP 1326858 A2	16-07-2003
			NO 20031744 A	14-06-2003
			WO 0232893 A2	25-04-2002
			US 2003045519 A1	06-03-2003
WO 0236589	A	10-05-2002	ES 2172436 A1	16-09-2002
			AU 2365502 A	15-05-2002
			CA 2427589 A1	10-05-2002
			WO 0236589 A1	10-05-2002
			EP 1330453 A1	30-07-2003
WO 02072570	A	19-09-2002	WO 02072570 A2	19-09-2002
			US 2003109564 A1	12-06-2003
WO 02072093	A	19-09-2002	WO 02072093 A2	19-09-2002
			US 2002151565 A1	17-10-2002

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record.

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.